Schering-Plough Pty Ltd

17 PBAC submissions on file, active 2005–2010. 82% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Infliximab
  Rheumatology · Recommended with restriction · 2025other sponsor
• Golimumab
  Rheumatology · Recommended with restriction · 2018other sponsor
• Posaconazole
  Infectious disease · Recommended · 2015other sponsor
• Corifollitropin alfa
  Women's health · Recommended with restriction · 2013other sponsor
• Doxorubicin hydrochloride, pegylated liposomal
  Haematology · Not recommended · 2008—
• Olmesartan medoxomil with amlodipine
  Cardiovascular · Recommended with restriction · 2010—
• Olmesartan medoxomil with hydrochlorothiazide
  Cardiovascular · Recommended with restriction · 2007—
• Peginterferon alfa-2b
  Gastroenterology · Recommended with restriction · 2005—
• Ribavirin
  Hepatology · Recommended · 2016other sponsor

Therapy area mix

Activity by year

2005 (1) · 2006 (3) · 2007 (3) · 2008 (4) · 2010 (6)

Rejection patterns

Across 3 Not recommended decisions on file.

• 1×uncertainty regarding comparative effectiveness in pregnancy rates (ENSURE trial underpowered for this outcome)
• 1×increased OHSS risk in non-normal responders (excluded from trials)
• 1×adverse events leading to discontinuation higher in corifollitropin arm
• 1×increased cost to PBS despite cost minimisation approach
• 1×financial analysis did not account for remaining day 8 treatment costs